The U.S. Food and Drug Administration (FDA) is poised to reconsider restrictions on certain research peptides, drugs that have garnered a devoted following despite scant evidence of safety and efficacy in humans. An advisory committee meeting scheduled for July 23-24 will evaluate seven specific peptides, potentially allowing compounding pharmacies to produce and dispense them legally, a move that would effectively legitimize an existing gray market.
What Are Peptides and Why the Debate?
Peptides are short-chain amino acids that include both well-established drugs like insulin and newer blockbusters such as GLP-1 weight loss medications. However, a growing number of so-called research peptides—not intended for human consumption—are sold online as wellness aids. These products, often produced by gray market compounding pharmacies, are promoted by social media influencers and figures like Joe Rogan. Consumers inject them in hopes of combating aging, weight loss, or muscular issues, according to Mohammed Chammout, a retail pharmacist in Michigan.
“There are a lot of patients who are foaming at the mouth waiting for these peptides to get moved to Category 1 legal status,” Chammout said.
Limited Evidence and Safety Concerns
Evidence for the safety and efficacy of these peptides in humans ranges from thin to nonexistent, depending on the compound. Dr. Eric Topol, director of the Scripps Research Translational Institute, called for caution. “The ban is appropriate for these peptides that have no data and all sorts of concerns regarding safety,” he said.
For example, BPC-157, sometimes called the “wolverine peptide,” is marketed for injury recovery based on animal studies primarily from one Croatian research group. Dr. Flynn McGuire, who studied the research, told Stat and Undark in 2025 that “the amount of hype to evidence is just so skewed, it’s crazy” and that the peptide “should not be used by humans.”
FDA Advisory Committee Meeting
The committee will discuss seven peptides: BPC-157, KPV, TB-500, MOTs-C, Emideltide, Semax, and Epitalon. The panel includes three voting members, six vacancies, and one non-voting member from the pharmaceutical industry. While the FDA is not bound to follow the committee’s advice, it typically does. Even if restrictions are eased, the drugs will not be FDA-approved; approval requires years of phased clinical trials, which most drugs fail.
Consumer advocacy group Public Citizen has called for full approval rather than a more lenient workaround.
Political and Industry Pressures
The push for change follows a 2023 Biden administration ban on compounding pharmacies producing 19 research peptides due to safety risks, including priapism and tumor growth. Health Secretary Robert F. Kennedy Jr. recently called the ban “illegal” on The Joe Rogan Experience. Critics worry the regulatory change is a foregone conclusion, given Kennedy’s influence. He has used peptides himself and is a “big fan,” according to his statements.
Topol expressed concern: “Whatever RFK is pushing for will somehow get done.” He cited Kennedy’s efforts to reduce childhood vaccines, which included firing all 17 members of a federal vaccine advisory committee and replacing them with allies, though a court later blocked the changes.
Industry and Physician Divide
A poll indicates 90% of physicians worry about patients self-directing peptide use, while compounding pharmacies argue that legalization would provide a safer supply. Dr. Anant Vinjamoori, chief medical officer of Hims (part of Hims & Hers), said “the evidence base is still developing” and noted that preclinical evidence is not no evidence. Wall Street analysts estimate telehealth peptide prescribing could reach $2.2 billion annually, with Hims & Hers potentially capturing $440 million if restrictions ease.
Hims & Hers acquired a U.S.-based peptide facility in 2025 but did not respond to questions about its expected market share.
